Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

Inclusion Criteria: * Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in accordance with the protocol. * Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Women of childbearing potential must have a negative pregnancy test at Baseline/Month 0. * Patients must be willing and able to give informed consent. Exclusion Criteria: * Serious or severe, test drug-related (probable or definite) adverse reaction in study TVP 1012/133. * Premature discontinuation from study TVP 1012/133 for any reason. * A clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases; or malignancies, as determined by medical history, physical exam, skin evaluation, laboratory tests, chest x-ray, or electrocardiogram (ECG).